Armata Pharmaceuticals Inc
AMEX:ARMP
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.98
3.93
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ARMP stock under the Base Case scenario is 1.61 USD. Compared to the current market price of 2.25 USD, Armata Pharmaceuticals Inc is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Armata Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ARMP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Armata Pharmaceuticals Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Armata Pharmaceuticals Inc
Balance Sheet Decomposition
Armata Pharmaceuticals Inc
Current Assets | 30.9m |
Cash & Short-Term Investments | 26.4m |
Receivables | 1.2m |
Other Current Assets | 3.3m |
Non-Current Assets | 77.4m |
PP&E | 57.1m |
Intangibles | 13.7m |
Other Non-Current Assets | 6.5m |
Current Liabilities | 123.2m |
Accounts Payable | 3.4m |
Accrued Liabilities | 8.2m |
Short-Term Debt | 48.3m |
Other Current Liabilities | 63.3m |
Non-Current Liabilities | 31.2m |
Other Non-Current Liabilities | 31.2m |
Earnings Waterfall
Armata Pharmaceuticals Inc
Revenue
|
3.7m
USD
|
Operating Expenses
|
-49.6m
USD
|
Operating Income
|
-45.9m
USD
|
Other Expenses
|
-21.1m
USD
|
Net Income
|
-67m
USD
|
Free Cash Flow Analysis
Armata Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
ARMP Profitability Score
Profitability Due Diligence
Armata Pharmaceuticals Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Armata Pharmaceuticals Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
ARMP Solvency Score
Solvency Due Diligence
Armata Pharmaceuticals Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Armata Pharmaceuticals Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARMP Price Targets Summary
Armata Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ARMP is 7.14 USD with a low forecast of 7.07 USD and a high forecast of 7.35 USD.
Dividends
Current shareholder yield for ARMP is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ARMP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
Contact
IPO
Employees
Officers
The intrinsic value of one ARMP stock under the Base Case scenario is 1.61 USD.
Compared to the current market price of 2.25 USD, Armata Pharmaceuticals Inc is Overvalued by 28%.